Compare ADMA Biologics Inc (ADMA) vs Bank of America Corp (BAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Bank of America Corp — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Bank of America Corp trades at $64.23 (market cap $447.54B). The key difference: Bank of America Corp is far larger — about 201.6× ADMA Biologics Inc's market cap, and Bank of America Corp pays a 2% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BAC | |
|---|---|---|
Market Cap | $2.22B | $447.54B |
Sector | Health | Financials |
52-Week High | $20.38 | $64.00 |
52-Week Low | $7.60 | $46.72 |
Enterprise Value | $2.29B | — |
Volume | — | 55,637,172 |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Bank of America (BAC) trades at $63.86, up 1.09% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, with Q2 2026 EPS of $1.21 beating expectations and revenue growth to $113.10B in 2025. Analyst consensus is strongly positive, with a $67.36 price target and 35 buy ratings. Recent news highlights strategic partnerships and hiring initiatives, reinforcing growth prospects.
BAC presents a favorable investment opportunity driven by earnings beats, robust deposit franchise, and potential capital returns post-stress tests. Risks include interest rate sensitivity and macroeconomic volatility. The stock's current valuation at a P/E of 14.78 offers room for upside relative to historical averages, supported by institutional bullishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →
